Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

83.07USD
2:58pm EST
Change (% chg)

$0.18 (+0.22%)
Prev Close
$82.89
Open
$83.09
Day's High
$83.32
Day's Low
$82.83
Volume
203,928
Avg. Vol
887,076
52-wk High
$89.01
52-wk Low
$64.25

Latest Key Developments (Source: Significant Developments)

Leap Therapeutics announces $18 million private placement offering
Wednesday, 15 Nov 2017 07:00am EST 

Nov 15 (Reuters) - Leap Therapeutics Inc ::Announces $18 million private placement offering.Upon closing of transaction, leap will sell 2.96 million shares of unregistered common stock​.Signed voting agreement with HealthCare Ventures to vote shares in favor of approval proposed at stockholders​ special meeting.To sell shares in private placement with select institutional investors, strategic partners, including HealthCare Ventures, Eli Lilly.  Full Article

ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT IN EUROPE
Friday, 10 Nov 2017 11:31am EST 

Nov 10 (Reuters) - Elanco Animal Health::ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE.CO, ARATANA THERAPEUTICS ANNOUNCED EMA'S CVMP ADOPTED POSITIVE OPINION TO RECOMMEND MARKETING AUTHORIZATION OF GALLIPRANT IN EU.FOLLOWING THE POSITIVE OPINION, EC WILL COMPLETE REGULATORY PROCESS FOR FINAL DECISION ON MARKETING AUTHORISATION IN EARLY 2018.  Full Article

Eagle Pharmaceuticals Q3 earnings per share $0.98
Wednesday, 8 Nov 2017 06:50am EST 

Nov 8 (Reuters) - Eagle Pharmaceuticals Inc :Eagle Pharmaceuticals Inc reports third quarter 2017 results.Q3 adjusted non-GAAP earnings per share $1.22.Q3 earnings per share $0.98.Q3 revenue $63 million versus I/B/E/S view $51.9 million.Q3 earnings per share view $0.80 -- Thomson Reuters I/B/E/S.Expect full year 2017 research and development expense will be consistent with upper end of $31-$35 million range​.Plan to begin dosing patients in Fulvestrant study in a few weeks and expect to file an NDA in Q4 of 2018​.Expect full year 2017 SG&A expense to be in range of $67 million - $70 million, slightly higher than previous guidance​.Will continue purchasing up to an additional $100 million shares under current share repurchase plan​.On PEMFEXY, says "hope to find a way to market" as soon as possible, once co's litigation with Eli Lilly is resolved​.  Full Article

‍Kymera Therapeutics announces $30 mln series A financing round​
Monday, 30 Oct 2017 07:00am EDT 

Oct 30 (Reuters) - :‍Kymera Therapeutics Llc announces $30 million series a financing round​.‍Kymera Therapeutics Llc - financing round was led by Atlas Venture, along with Lilly Ventures and Amgen Ventures​.  Full Article

Lilly "very optimistic" on U.S. prospect for arthritis drug
Tuesday, 24 Oct 2017 10:35am EDT 

Oct 24 (Reuters) - Eli Lilly And Co :Eli Lilly says "very optimistic" on U.S. prospect for arthritis drug baricitinib; still sees resubmission to FDA by January.  Full Article

Eli Lilly reports Q3 EPS $0.53
Tuesday, 24 Oct 2017 06:25am EDT 

Oct 24 (Reuters) - Eli Lilly And Co :Lilly reports third-quarter results, announces strategic review of Elanco Animal Health.Q3 earnings per share $0.53.Sees FY 2017 revenue $22.4 billion to $22.7 billion.Q3 revenue $5.658 billion versus I/B/E/S view $5.52 billion.Q3 earnings per share view $1.03 -- Thomson Reuters I/B/E/S.Sees FY 2017 non-GAAP earnings per share $4.15 to $4.25.Sees FY 2017 earnings per share $1.73 to $1.83.‍Reviewing strategic alternatives for Elanco Animal Health, including an initial public offering, merger, sale​.‍For Q3 of 2017, Alimta generated worldwide revenue of $514.5 million, which decreased 10 percent compared with Q3 of 2016​.Qtrly ‍non-GAAP eps $1.05​.Qtrly Cymbalta sales $‍​183.2 million versus $313.5 million.‍Company's worldwide Jardiance revenue during Q3 of 2017 was $127.2 million, an increase of 168 percent compared with Q3 of 2016​.‍Review of strategic alternatives for Elanco Animal Health may also include retention of the business.FY2017 earnings per share view $4.16, revenue view $22.51 billion -- Thomson Reuters I/B/E/S.‍In Q3 of 2017, company recognized asset impairment, restructuring and other special charges of $406.5 million​.Co will provide an update on ​‍review of strategic alternatives for Elanco Animal Health no later than middle of 2018.‍Is exploring strategic options for Posilac, including seeking a buyer for molecule and its Augusta manufacturing site​.  Full Article

Lilly announces $72 million investment in diabetes manufacturing in Indianapolis
Monday, 23 Oct 2017 06:45am EDT 

Oct 23 (Reuters) - Eli Lilly And Co :Lilly announces $72 million investment in diabetes manufacturing in Indianapolis.Eli Lilly and Co - ‍investment will be used to replace an existing insulin vial filling line and allow Lilly to meet "growing demand" for its insulins​.  Full Article

Eli Lilly ‍declares Q4 dividend of $0.52/share
Monday, 16 Oct 2017 03:32pm EDT 

Oct 16 (Reuters) - Eli Lilly And Co ::Declared a dividend for Q4 of 2017 of $0.52 per share on outstanding common stock​.  Full Article

FDA grants priority review for Lilly's verzenio
Thursday, 12 Oct 2017 06:45am EDT 

Oct 12 (Reuters) - Eli Lilly And Co ::FDA grants priority review for potential new indication for Lilly's verzenio (abemaciclib) as initial treatment of advanced breast cancer.Eli Lilly And Co - ‍FDA's goal is to take action within eight months of receiving an application, compared with standard review timeframe of 12 months​.  Full Article

‍BIOLOGICS SAYS SELECTED BY ELI LILLY TO BE IN LIMITED DISTRIBUTION NETWORK FOR VERZENIO​
Wednesday, 11 Oct 2017 11:21am EDT 

Oct 11 (Reuters) - Biologics Inc::‍BIOLOGICS INC SAYS HAS BEEN SELECTED BY ELI LILLY AND COMPANY TO BE IN LIMITED DISTRIBUTION NETWORK FOR VERZENIO​.  Full Article

Lilly mulls sale, other options for animal health business

Eli Lilly and Co said on Tuesday it is considering the sale of its Elanco animal health business and expressed optimism that its rejected rheumatoid arthritis drug would pass muster with U.S. regulators when it resubmits its application.